Mylan Pharmaceuticals ULC

Mylan Pharmaceuticals ULC

March 17, 2011 17:11 ET

Mylan Pharmaceuticals ULC in Canada Voluntarily Recalls Portion of Product Lot No. 1037180

TORONTO, ONTARIO--(Marketwire - March 17, 2011) - Mylan Pharmaceuticals ULC in Canada today announced that it is voluntarily recalling all 100-count bottles of a single product lot, number 1037180, which were distributed to wholesalers and pharmacies. The company received a report from a pharmacist who had received several bottles of Mylan-Minocycline Capsules, 50 mg, including one bottle that was mislabeled as another product (Mylan-Amlodipine Tablets, 5 mg). The mislabeled bottle did contain Mylan-Minocycline Capsules, 50 mg. The company has notified Health Canada of this action. The 250-count bottles that were distributed to wholesalers and pharmacies with the same lot number are not part of this recall.

Mylan Pharmaceuticals ULC President Dick Guest said: "We are recalling this product because patient safety is of utmost concern for all of us at Mylan. There can be a risk of an adverse event if any patient mistakenly takes a medication that has not been prescribed for them. In some cases, these risks can be serious, depending on the product and the individual patient."

Mylan also is in the process of contacting pharmacists who may have received product from this lot and is advising them to contact patients who had an Amlodipine prescription filled on or after Sept. 13, 2010, the date when this Minocycline lot was released to the Canadian market, to ensure that they did not receive mislabeled product. Patients should contact their pharmacists and/or physicians if they have any questions.

Mylan-Minocycline, a generic version of Minocin®, is an antibiotic indicated for the treatment of various types of infections. Mylan-Amlodipine, a generic version of Norvasc®, is used to treat hypertension (high blood pressure) and angina (chest pain).

Customers or patients who have additional questions should call Mylan Pharmaceuticals ULC Customer Service at 1.800.575.1379.

Contact Information

    Michael Laffin (Media)
    Kris King (Investors)